Scientists test new Weight-Loss Pill's hidden side effects with common drugs
NCT ID NCT07065058
Summary
This early-stage study aimed to understand how a new oral drug for obesity, called VCT220, might interact with three common medications (repaglinide, rosuvastatin, and digoxin). It enrolled 24 healthy, overweight, and obese volunteers to see if VCT220 changes how the body processes these other drugs. The main goal was to gather safety and interaction data, not to test VCT220's effectiveness for weight loss.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Second University Hospital
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.